Utah committee advances bill to auto-align state drug schedules with federal changes, drawing opposition

Senate Health and Human Services Committee passed SB 83 on a voice vote after a half-hour of sponsor remarks and public testimony.

Senator Vickers, the bill sponsor, said the measure is designed to "start where the federal government starts" when the federal government (through FDA/DEA) places a pharmaceutical composition into a controlled-substance schedule, while preserving the state’s Controlled Substances Advisory Council and Utah’s ability to impose stricter scheduling when appropriate. "We can be more stringent in the state. We can't be less," he told the committee during his presentation.

The bill drew public opposition from advocacy groups. Walter Plumb, president of Drug Safe Utah, told the committee the bill’s automatic-rescheduling language is "too broad" and could undercut separate state efforts such as the proposed psilocybin framework (Sen. Cullimore’s bill) or previous Utah action that reclassified ketamine at the state level. Plumb said the bill’s phrase that a federally rescheduled pharmaceutical "is deemed scheduled under this section" risked reversing prior state determinations.

Danny Bordeaux of the Utah Eagle Forum also opposed the bill, testifying that automatic federal alignment would strip local safeguards and make it easier to "loosen restrictions on a dangerous substance." Both witnesses urged the committee to narrow the automatic-rescheduling language.

Vickers responded that SB 83 would not automatically roll back medications already rescheduled by the state and reiterated that FDA approval remains a threshold for pharmacy availability. He said the advisory council remains the mechanism to recommend stricter state scheduling if warranted.

The committee voted to recommend SB 83 favorably to the full Senate.

What’s next: SB 83 moves to the Senate floor for further debate and any amendments. The sponsor said legislative staff and the advisory council process remain available for additional scrutiny of specific substances mentioned during testimony.